Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical oncology company whose news flow is closely tied to the development of its lead investigational therapy, ivonescimab (SMT112 in Summit’s territories). Ivonescimab is described by the company as a potential first-in-class bispecific antibody targeting PD-1 and VEGF in a single molecule, and it is being evaluated in multiple Phase III clinical trials in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
News about Summit frequently covers clinical milestones for ivonescimab, including updates from the global Phase III HARMONi trial in EGFR-mutated NSCLC after third-generation EGFR TKI therapy, as well as HARMONi-3 and HARMONi-7 in first-line metastatic NSCLC and HARMONi-GI3 in first-line unresectable metastatic CRC. Company announcements have highlighted progression-free survival and overall survival data, hazard ratios, response rates, and safety profiles, along with presentations at major conferences such as the World Conference on Lung Cancer, SITC, and ESMO.
Investors following SMMT news will also see regulatory and corporate updates, including Summit’s submission of a Biologics License Application to the U.S. FDA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, Fast Track designation for the HARMONi setting, and summaries of Akeso’s HARMONi-A trial in China, which demonstrated a statistically significant overall survival benefit for ivonescimab plus chemotherapy versus chemotherapy alone.
Additional news items cover financing activities such as private placements and at-the-market offerings, inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), and collaboration announcements. Notably, Summit has reported a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s investigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), across multiple solid tumor settings including small cell lung cancer.
For readers tracking SMMT, the news stream provides insight into Summit’s late-stage oncology pipeline, regulatory interactions, capital-raising efforts, and partnerships that shape the company’s development path.
Summit Therapeutics (NASDAQ: SMMT) reported its Q2 2022 financial results, showing a net loss of $16.8 million, an improvement from $24.4 million in Q2 2021. As of June 30, 2022, the company held $57.3 million in cash, down from $71.8 million at the end of 2021. A Rights Offering raised $100 million, netting approximately $99.9 million after costs, allowing the repayment of a $25 million note. Operating cash outflow for the first half of 2022 was $38.2 million. The company continues to receive funding from BARDA and CARB-X for ongoing clinical trials.
On August 9, 2022, Summit Therapeutics (NASDAQ: SMMT) announced the successful completion of a fully-subscribed $100 million rights offering. This initiative resulted in the sale of approximately 103 million shares at $0.97 per share, yielding net proceeds of about $99.9 million after offering expenses. Robert W. Duggan and Dr. Maky Zanganeh participated in the offering, securing additional shares. The company aims to utilize these funds to further its mission in improving human health. The rights offering allowed shareholders to prevent dilution of their current stakes.
Summit Therapeutics Inc. (NASDAQ: SMMT) has provided a preliminary update regarding its financial position and its rights offering. The offering, set to expire on August 8, 2022, could raise up to $100 million. The subscription price per share will be the lesser of $1.08 or the volume-weighted average price over the five days leading to the expiration. As of June 30, 2022, Summit reported at least $73 million in cash and receivables, indicating it can meet operational needs into Q3 2023.
Summit Therapeutics Inc. (NASDAQ: SMMT) has appointed Dr. Maky Zanganeh as Co-Chief Executive Officer & President, effective immediately. Previously serving as Chief Operating Officer since November 2020, Dr. Zanganeh brings extensive industry experience, having led Pharmacyclics' clinical development and a $21 billion acquisition by AbbVie. Robert W. Duggan remains Chairman and CEO, expressing confidence in the leadership team's ability to expand the company's pipeline and address high unmet medical needs, particularly in oncology and infectious diseases. Dr. Zanganeh's leadership is anticipated to positively impact Summit's growth.
Summit Therapeutics Inc. (NASDAQ: SMMT) has initiated a rights offering to raise up to $100 million through the sale of common stock. Stockholders as of July 5, 2022, will receive non-transferable subscription rights, allowing them to purchase shares at an initial price of $1.08 or a lower volume-weighted average price determined by trading days up to August 8, 2022. The excess subscription amounts can be applied to additional shares if the alternate price is lower. A prospectus supplement was filed with the SEC on July 18, 2022, detailing the terms of the offering.
Summit Therapeutics Inc. (NASDAQ: SMMT) has provided an update on its clinical development of ridinilazole for treating C. difficile infections. Following a recent Type C meeting with the FDA, the company discussed potential pathways for marketing authorization, likely requiring at least one additional trial. Moreover, Summit plans to present Ri-CoDIFy Phase III trial results at IDWeek 2022 in October, showcasing its international study comparing ridinilazole and vancomycin in 759 patients. The trial was partially funded by BARDA, emphasizing the company's commitment to advancing novel therapies.
Summit Therapeutics Inc. (SMMT) announced a rights offering for holders of its common stock as of July 5, 2022. The offering allows participants to purchase shares at $1.08 or the average price over the last five trading days before the expiration date, expected on August 5, 2022. The company aims to raise up to $100 million, with significant participation indicated from CEO Robert W. Duggan and COO Dr. Maky Zanganeh. The rights offering details will be registered with the SEC, and the company emphasizes its commitment to developing effective therapies.
Summit Therapeutics Inc. (NASDAQ: SMMT) has rescheduled its Annual Shareholders’ Meeting to June 16, 2022, at 1:00 PM Eastern Time, now set for a virtual format. This change allows shareholders ample time to adjust their plans for attendance. To participate in voting or submitting questions, attendees must log in with a unique control number from their proxy statement received by April 26, 2022. The company aims to develop beneficial healthcare solutions, while emphasizing their commitment to stakeholder engagement and responsible governance.
Summit Therapeutics (NASDAQ: SMMT) has appointed Ankur Dhingra as Chief Financial Officer, effective immediately. Dhingra brings over 20 years of finance experience from his previous role at CAREDx, Inc., where he oversaw finance, market access, and IT. His leadership is expected to play a crucial role in expanding Summit's pipeline through collaborations and acquisitions. Dhingra will also manage the company's information technology and human resources functions. The company's mission focuses on developing therapies aimed at improving patient lives.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported financial results for Q1 2022, highlighting a cash balance of $77.5 million, up from $71.8 million in Q4 2021. The company incurred a net loss of $21.4 million, compared to $17.5 million in Q1 2021. Notably, the company secured $1.5 million in funding from BARDA for clinical trials, with a total of $57.9 million received under a potential $72.5 million contract. Summit plans to expand its pipeline in oncology and infectious diseases and will communicate data from its Phase III trial later this year.